Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Sudy of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Grants and Contracts Details

StatusActive
Effective start/end date10/10/185/10/23

Funding

  • Celgene International II Sarl: $83,149.00